Skip to main content

FairJourney Bio Launches Cryo-EM Services With Advanced Laboratories in San Diego, USA

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Expanded offering provides high-resolution structural insights to support antibody discovery and biologic design

FairJourney Bio (FJBio), a leading global provider of antibody discovery and development services, today announced the expansion of its portfolio with the launch of state-of-the-art cryo-electron microscopy (cryo-EM) services, supported through the Company’s advanced laboratories in San Diego, CA.

This strategic addition strengthens FJBio’s position as a trusted partner for pharmaceutical and biotechnology companies worldwide by providing accessible, high-resolution structural insights that accelerate antibody discovery, selection, and design. By combining cutting-edge technology with FJBio’s team of expert scientists, the service offering ensures partners gain access to top-quality data and receive comprehensive guidance throughout the discovery and development process.

Benefitting from industry-leading, high-throughput cryo-EM capabilities, utilizing two state-of-the-art ThermoFisher Titan Krios 5 systems, the cryo-EM services enable rapid and scalable analysis, with models delivered within 2-3 weeks from sample delivery. The offering supports both intermediate- and high-resolution validation of proteins, protein-protein, and protein-ligand complexes, producing high-quality and highly interpretable protein structures to inform confident decision-making.

Tailored specifically for antibody discovery, the cryo-EM services deliver value across the R&D value chain, supporting programs from early evaluation through to advanced optimization:

  • Evaluation – Early structural insights into epitope diversity of immune libraries
  • Discovery – cryo-EM-based hit discovery supported by sequence-from-structure workflows
  • Selection – Structure-informed insights into therapeutic binding modes to guide lead selection
  • Control – Computational protein design campaigns and development of next-generation synthetic libraries

Dr. Werner Lanthaler, Chief Executive Officer of FairJourney Bio, commented:Cryo-EM enables unique and powerful insights into molecular structures and interactions at an atomic level. Adding structure-based information from real-world images is a paradigm shift that allows researchers to de-risk their R&D projects along the entire value chain. The improved resolution removes guesswork at critical junctures in the R&D process and thus serves to both accelerate discovery projects as well as improving their success rates. FJBio’s cryo-EM platform with a dedicated team of experts is unmatched in terms of speed, scale and quality.”

With the addition of cryo-EM services, supported by our high-end San Diego labs, we can provide our partners with the structural precision and expert support needed to accelerate the development of next-generation therapies,” said Dr. Christopher Arthur, CSO Structural Biology, FairJourney Bio.

For more information, visit: https://fjbio.com/fjb-cryo-em

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  236.92
+2.81 (1.20%)
AAPL  294.48
+0.18 (0.06%)
AMD  507.88
-11.98 (-2.30%)
BAC  57.77
-0.14 (-0.25%)
GOOG  342.33
-3.75 (-1.08%)
META  559.21
-3.00 (-0.53%)
MSFT  368.82
-5.12 (-1.37%)
NVDA  197.19
-2.85 (-1.43%)
ORCL  155.89
-9.27 (-5.61%)
TSLA  374.26
-7.35 (-1.93%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.